Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
Status:
RECRUITING
Trial end date:
2026-10-18
Target enrollment:
Participant gender:
Summary
To explore the safety and efficacy of nanobody-based BCMA-targeting biepitope CAR-T cells in the treatment of relapsed/refractory multiple myeloma，this study will be conducted in multiple study centers, with 60 patients openly enrolled to receive CAR-T cell therapy. Patients participating in clinical trials will be tested and evaluated for treatment safety, efficacy, duration of response, and long-term survival.
Phase:
PHASE1
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators:
Hebei Taihe Chunyu Biotechnology Co., Ltd Huazhong University of Science and Technology Union Shenzhen Hospital The Seventh Affiliated Hospital of Sun Yat-sen University